Skip to main content

Alzheimer’s Network for Treatment and Diagnostics (ALZ-NET)

January 20, 2026
This study will gather information about patients who are taking new medicines for Alzheimer’s disease. We’ll keep an eye on how these patients are doing in the long run, tracking things like how they’re responding to treatment, what their overall health outcomes are like, and how safe these new treatments...

Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-2)

January 20, 2026
Brief Summary To compare the efficacy and safety of remibrutinib versus teriflunomide in patients with relapsing multiple sclerosis (RMS) Detailed Description The study CLOU064C12302 consists of an initial Core Part (CP) (maximum duration per participant of up to 30 months), followed by an Extension Part (EP, of up to 5...

Pediatric Ravulizumab Study

January 20, 2026
A phase 3, open-label, single-arm, multicenter study to evaluate the pharmacokinetics, pharmacodynamics, efficacy, safety, and immunogenicity of Ravulizumab administered intravenously in pediatric participants (6 to <18 years of age) with generalized myasthenia gravis (gMG).

Non-Invasive Brain Activity Recording and Behavior Research Study

January 20, 2026
The purpose of this research study is to learn if and how non-invasive brain stimulation influences motivation problems in Parkinson’s disease. Men and women aged 55-80 years with Parkinson’s disease for at least 5 years can join the study. There are three study visits. Participation will involve answering questions, doing...

ARGX-113-2011

January 20, 2026
A Phase 3, Single-Arm, Multicenter, Open-label Extension of Study ARGX-113-2007 to Investigate the Long-term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy

Parkinson’s Disease Motivation Study

January 20, 2026
Apathy, defined as lack of enthusiasm or concern for previously exciting or interesting things, is a very common, debilitating, often refractory symptom, and is associated with poor outcomes in neurologic and psychiatric conditions. Transcranial magnetic stimulation (TMS), a form of non-invasive brain stimulation, is effective in treating depression but has...

Lumosa BRIGHT

January 20, 2026
A Phase II, Double Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Multiple Doses of LT3001 Drug Product in Subjects with Acute Ischemic Stroke (AIS) (BRIGHT)

Rett Syndrome Real World Data Observational Registry

January 20, 2026
The Rett Syndrome Registry is a longitudinal observational study of individuals with MECP2 mutations and a diagnosis of Rett syndrome. Designed together with the IRSF Rett Syndrome Center of Excellence Network medical directors, this study collects data on the signs and symptoms of Rett syndrome as reported by the Rett...

Prospective Data Collection for DBS Outcomes Prediction

October 14, 2025
We are using specialized functional MRI for people receiving deep brain stimulation surgery to help predict who will benefit most from this procedure.

Biomarkers in the Brain Optimization in Severe Traumatic Brain Injury Trial (Bio-BOOST)

October 14, 2025
BioBOOST is a multicenter, observational study of the effect of derangements in brain physiologic parameters on brain injury biomarker levels in patients with severe traumatic brain injury. Detailed Description Traumatic brain injury (TBI) remains a major cause of death and disability, with an estimated cost of $45 billion/year in the...